- Home
- MDXH vs AVTX Comparison
MDXH vs AVTX Comparison
Compare MDXH & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- AVTX
- Stock Information
- Founded
- MDXH 2003
- AVTX 2011
- Country
- MDXH Belgium
- AVTX United States
- Employees
- MDXH N/A
- AVTX N/A
- Industry
- MDXH
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- AVTX Health Care
- Exchange
- MDXH Nasdaq
- AVTX Nasdaq
- Market Cap
- MDXH 141.1M
- AVTX 126.9M
- IPO Year
- MDXH 2021
- AVTX 2015
- Fundamental
- Price
- MDXH $3.55
- AVTX $9.29
- Analyst Decision
- MDXH Buy
- AVTX Strong Buy
- Analyst Count
- MDXH 1
- AVTX 8
- Target Price
- MDXH $6.00
- AVTX $31.00
- AVG Volume (30 Days)
- MDXH 172.3K
- AVTX 306.4K
- Earning Date
- MDXH 08-05-2025
- AVTX 08-07-2025
- Dividend Yield
- MDXH N/A
- AVTX N/A
- EPS Growth
- MDXH N/A
- AVTX N/A
- EPS
- MDXH N/A
- AVTX N/A
- Revenue
- MDXH $98,953,000.00
- AVTX $441,000.00
- Revenue This Year
- MDXH $24.77
- AVTX N/A
- Revenue Next Year
- MDXH $22.21
- AVTX N/A
- P/E Ratio
- MDXH N/A
- AVTX N/A
- Revenue Growth
- MDXH 22.56
- AVTX N/A
- 52 Week Low
- MDXH $1.35
- AVTX $3.39
- 52 Week High
- MDXH $3.81
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- MDXH 73.83
- AVTX 62.48
- Support Level
- MDXH $2.86
- AVTX $9.16
- Resistance Level
- MDXH $3.81
- AVTX $9.84
- Average True Range (ATR)
- MDXH 0.22
- AVTX 0.68
- MACD
- MDXH 0.05
- AVTX -0.10
- Stochastic Oscillator
- MDXH 78.15
- AVTX 50.09
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).